Matches in Wikidata for { <http://www.wikidata.org/entity/Q37304878> ?p ?o ?g. }
- Q37304878 description "article científic" @default.
- Q37304878 description "article scientifique" @default.
- Q37304878 description "articolo scientifico" @default.
- Q37304878 description "artigo científico" @default.
- Q37304878 description "artículu científicu espublizáu en 2007" @default.
- Q37304878 description "bilimsel makale" @default.
- Q37304878 description "scientific article published on 20 July 2007" @default.
- Q37304878 description "vedecký článok" @default.
- Q37304878 description "vetenskaplig artikel" @default.
- Q37304878 description "videnskabelig artikel" @default.
- Q37304878 description "vědecký článek" @default.
- Q37304878 description "wetenschappelijk artikel" @default.
- Q37304878 description "wissenschaftlicher Artikel" @default.
- Q37304878 description "наукова стаття, опублікована в липні 2007" @default.
- Q37304878 description "научни чланак" @default.
- Q37304878 description "مقالة علمية نشرت في 20 يوليو 2007" @default.
- Q37304878 name "A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye" @default.
- Q37304878 name "A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye" @default.
- Q37304878 name "A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye" @default.
- Q37304878 type Item @default.
- Q37304878 label "A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye" @default.
- Q37304878 label "A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye" @default.
- Q37304878 label "A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye" @default.
- Q37304878 prefLabel "A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye" @default.
- Q37304878 prefLabel "A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye" @default.
- Q37304878 prefLabel "A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye" @default.
- Q37304878 P1433 Q37304878-D03E43CF-F16E-49E4-BFD7-124B18F88FBB @default.
- Q37304878 P1476 Q37304878-B8792E50-389F-4BFE-B3BC-C8A4FCE72245 @default.
- Q37304878 P2093 Q37304878-1DEC438D-F605-44FD-86FC-FB1EBD67F189 @default.
- Q37304878 P2093 Q37304878-85A2C9E2-B45F-4AEE-B6E4-9877B8897C34 @default.
- Q37304878 P2093 Q37304878-CB30A304-E3EC-4FF5-9F11-BBF90A08D506 @default.
- Q37304878 P2093 Q37304878-D29D9A49-5F2E-4704-94F5-1787B2AF5574 @default.
- Q37304878 P2093 Q37304878-E0A55C83-F0F6-443B-8621-635E9833AC12 @default.
- Q37304878 P2093 Q37304878-E89C2925-7F19-4886-B724-C8F80096384A @default.
- Q37304878 P2093 Q37304878-FAFBDA68-D242-4996-8FFC-392B5402A047 @default.
- Q37304878 P2093 Q37304878-FCA34EC9-4A99-4448-9424-7462E35F7372 @default.
- Q37304878 P2860 Q37304878-0A32EF6E-DD0D-4AA2-BB17-73BBCDE06A02 @default.
- Q37304878 P2860 Q37304878-0BA7DDBE-7370-4A44-81AD-076D2E2D55A8 @default.
- Q37304878 P2860 Q37304878-15E9777D-4435-4DAC-8A7D-EA98F542A148 @default.
- Q37304878 P2860 Q37304878-1A42035C-1696-465A-BA4B-F9B611D6B5A1 @default.
- Q37304878 P2860 Q37304878-206E27DC-6CCD-4089-AAE2-5803782DDB12 @default.
- Q37304878 P2860 Q37304878-215614E8-7ED3-47E8-8AC1-5396CC96EB49 @default.
- Q37304878 P2860 Q37304878-2655E15C-B0CF-4A92-8C6E-B0377EC26046 @default.
- Q37304878 P2860 Q37304878-34EDDDCB-DD0C-4B0A-B937-CB8D07A45DEC @default.
- Q37304878 P2860 Q37304878-35253237-95AC-4276-9544-407D88516D14 @default.
- Q37304878 P2860 Q37304878-4237FDBB-E92F-4387-834B-24EF21D63EE6 @default.
- Q37304878 P2860 Q37304878-45A11279-7D5E-42F6-A3C7-0C100FB42356 @default.
- Q37304878 P2860 Q37304878-4BCAD9CB-2AEB-4EF3-B061-38F25D2148D7 @default.
- Q37304878 P2860 Q37304878-4F7BB003-17CF-4E89-97E2-2BF04567AAA4 @default.
- Q37304878 P2860 Q37304878-51AB5703-4150-4163-87CD-5FF40A31A9F9 @default.
- Q37304878 P2860 Q37304878-5446FEB5-CFF6-4E04-AC4D-F521E3AA167A @default.
- Q37304878 P2860 Q37304878-5AFEC63D-B35F-4472-948E-74DCE2B5F152 @default.
- Q37304878 P2860 Q37304878-61A37403-8063-48EF-8733-50F5DCBBD9F2 @default.
- Q37304878 P2860 Q37304878-6CB31EF1-0C87-4CF4-93F2-18CE965AF045 @default.
- Q37304878 P2860 Q37304878-71CB9E51-1EA0-4A7E-A70D-0FAAAECE5683 @default.
- Q37304878 P2860 Q37304878-73E2DA55-9093-461C-A531-A0BF3869AA81 @default.
- Q37304878 P2860 Q37304878-73EF7B06-444D-40ED-9224-F89A9BC8D5FE @default.
- Q37304878 P2860 Q37304878-7563E9CB-D90F-4F0C-BD4C-FAE1B1ECBD05 @default.
- Q37304878 P2860 Q37304878-8008B3EF-9595-4A98-8510-31EA2108BEE8 @default.
- Q37304878 P2860 Q37304878-9DD834AD-DBA6-4ECD-A826-C1467E08E501 @default.
- Q37304878 P2860 Q37304878-9F8E84D3-F05B-4A0D-8875-1FF4C8815989 @default.
- Q37304878 P2860 Q37304878-A0E99656-47AE-4B04-A769-3EDB838A5807 @default.
- Q37304878 P2860 Q37304878-BD72A507-DEB7-40A5-BA79-61B874474270 @default.
- Q37304878 P2860 Q37304878-C0A194C5-B706-4F49-9CD4-A83D4A091263 @default.
- Q37304878 P2860 Q37304878-C9D7FEBE-6E65-41FE-9E1B-45E377BAD391 @default.
- Q37304878 P2860 Q37304878-CE3C9A91-791C-4948-BB27-473669D5F70A @default.
- Q37304878 P2860 Q37304878-DAE6E34E-7163-4CF9-8ABE-87580B8245AA @default.
- Q37304878 P2860 Q37304878-E2321553-6B4A-493C-9110-806FE1648732 @default.
- Q37304878 P2860 Q37304878-EA316964-ED3B-47D8-BE69-9857102BF0E1 @default.
- Q37304878 P2860 Q37304878-EFAE7DB0-5D98-4744-A878-ED7B39E353B5 @default.
- Q37304878 P2860 Q37304878-F2C2064A-A9E5-492B-BF30-C4D415BB88E8 @default.
- Q37304878 P2860 Q37304878-F510F7AC-1328-40C5-9E51-8DD596084A0F @default.
- Q37304878 P2860 Q37304878-F7968051-5496-4D7A-8FD4-6E6BA98E788F @default.
- Q37304878 P2860 Q37304878-FE50E0CB-9057-4D6E-9544-7243944C3434 @default.
- Q37304878 P304 Q37304878-D4D7FE6A-C424-4AAE-8DD3-9C2B603A50C3 @default.
- Q37304878 P31 Q37304878-CCB0CA1C-E6BC-47D7-AC47-FBF40B3BF368 @default.
- Q37304878 P356 Q37304878-AC72185B-C403-4A0B-9A8F-1C2C1733FA3F @default.
- Q37304878 P433 Q37304878-7CD9FABA-DFD5-4756-A16F-5573CD067D0F @default.
- Q37304878 P478 Q37304878-9529F1B3-730B-4EBE-A2EA-4F0394765998 @default.
- Q37304878 P50 Q37304878-3C1A73E4-666C-442D-B1E4-298AA2A6F0B3 @default.
- Q37304878 P577 Q37304878-81121CC3-D9BD-4B1D-9A07-FE8BD42DDE28 @default.
- Q37304878 P5875 Q37304878-2FB9B61E-D4CD-4C18-9A69-6843B530ECEE @default.
- Q37304878 P698 Q37304878-731186E3-1090-41CF-967F-C68633FEB32B @default.
- Q37304878 P932 Q37304878-DE13FFAB-5DDA-4614-9F86-0B0AC0AC3033 @default.
- Q37304878 P356 J.LEUKRES.2007.05.003 @default.
- Q37304878 P698 17640728 @default.
- Q37304878 P1433 Q15716445 @default.
- Q37304878 P1476 "A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye" @default.
- Q37304878 P2093 "Bonny Johnson" @default.
- Q37304878 P2093 "Francis J Giles" @default.
- Q37304878 P2093 "Ivana Gojo" @default.
- Q37304878 P2093 "Jacqueline Greer" @default.
- Q37304878 P2093 "Jennifer Low" @default.
- Q37304878 P2093 "Judith E Karp" @default.
- Q37304878 P2093 "Lawrence Morris" @default.
- Q37304878 P2093 "Mya Thein" @default.
- Q37304878 P2860 Q28619961 @default.
- Q37304878 P2860 Q33330553 @default.
- Q37304878 P2860 Q33503482 @default.
- Q37304878 P2860 Q34977300 @default.